Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-1f85f95883d4c92167ca0868ad5c50fd",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-1f85f95883d4c92167ca0868ad5c50fd",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-1f85f95883d4c92167ca0868ad5c50fd",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-1f85f95883d4c92167ca0868ad5c50fd\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-1f85f95883d4c92167ca0868ad5c50fd</b></p><a name=\"composition-en-1f85f95883d4c92167ca0868ad5c50fd\"> </a><a name=\"hccomposition-en-1f85f95883d4c92167ca0868ad5c50fd\"> </a><a name=\"composition-en-1f85f95883d4c92167ca0868ad5c50fd-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/15/990/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - ikervis</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/15/990/001"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp1f85f95883d4c92167ca0868ad5c50fd"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - ikervis",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What IKERVIS is and what it is used for</li><li>What you need to know before you use IKERVIS</li><li>How to use IKERVIS</li><li>Possible side effects</li><li>How to store IKERVIS</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What ikervis is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What ikervis is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>IKERVIS contains the active substance, ciclosporin. Ciclosporin belongs to a group of medicines known as immunosuppressive agents that are used to reduce inflammation.</p><p>IKERVIS is used to treat adults with severe keratitis (inflammation of the cornea, the transparent layer in the front part of the eye). It is used in those patients who have dry eye disease, which has not improved despite treatment with tear substitutes (artificial tears).</p><p>Talk to a doctor if you do not feel better or if you feel worse.</p><p>You should visit your doctor at least every 6 months to assess the effect of IKERVIS.</p></div>"
}
},
{
"title" : "2. What you need to know before you take ikervis",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take ikervis"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do NOT use IKERVIS</p><ul><li>if you are allergic to ciclosporin or any of the other ingredients of this medicine (listed in section 6).</li><li>if you have had or have a cancer in or around your eye.</li><li>if you have an eye infection.</li></ul><p>Warnings and precautions Only use IKERVIS for dropping in your eye(s).</p><p>Talk to your doctor or pharmacist before using IKERVIS</p><ul><li>if you have previously had an eye infection by the herpes virus that might have damaged the transparent front part of the eye (cornea).</li><li>if you are taking any medicines containing steroids.</li><li>if you are taking any medicines to treat glaucoma.</li></ul><p>Contact lenses can further damage the transparent front part of the eye (cornea). Therefore, you should remove your contact lenses at bedtime before using IKERVIS; you can reinsert them when you wake up.</p><p>Children and adolescents IKERVIS should not be used in children and adolescents below 18 years old.</p><p>Other medicines and IKERVIS Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.</p><p>Talk to your doctor if you are using eye drops containing steroids with IKERVIS as these might increase the risk of side effects.</p><p>IKERVIS eye drops should be used at least 15 minutes after any other eye drops are used.</p><p>Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.</p><p>IKERVIS should not be used if you are pregnant.</p><p>If you could become pregnant you must use contraception while using this medicine.</p><p>IKERVIS is likely to be present in breast milk in very small amounts. If you are breast feeding talk to your doctor before using this medicine.</p><p>Driving and using machines Your vision may be blurred immediately after using IKERVIS eye drops. If this happens, wait until your vision clears before you drive or use machines.</p><p>IKERVIS contains cetalkonium chloride This medicine contains 0.05 mg cetalkonium chloride in 1 mL. You should remove contact lenses before using this medicine and you can reinsert them when you wake up. Cetalkonium chloride may cause eye irritation. If you feel abnormal eye sensation, stinging or pain in the eye after using this medicine, talk to your doctor.</p></div>"
}
},
{
"title" : "3. How to take ikervis",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take ikervis"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose is one drop in each affected eye, once daily at bedtime.</p><p>Instructions for use Follow these instructions carefully and ask your doctor or pharmacist if there is anything you do not understand.</p><p>1 2 3</p><p>Wash your hands.</p><p>If you wear contact lenses, take them out at bedtime before using the drops; you can reinsert them when you wake up.</p><p>Open the aluminium pouch, which contains 5 single-dose containers.</p><p>Take one single-dose container from the aluminium pouch.</p><p>Gently shake the single dose container prior to use.</p><p>Twist off the cap (picture 1).</p><p>Pull down your lower eyelid (picture 2).</p><p>Tilt your head back and look up at the ceiling.</p><p>Gently squeeze one drop of the medicine onto your eye. Make sure you do not touch your eye with the tip of the single-dose container.</p><p>Blink a few times so that the medicine covers your eye.</p><p>After using IKERVIS, press a finger into the corner of your eye by the nose and close gently the eyelids for 2 minutes (picture 3). This helps to stop IKERVIS getting into the rest of the body.</p><p>If you use drops in both eyes, repeat the steps for your other eye.</p><p>Discard the single dose container as soon as you have used it, even if there is still some medicine left in it.</p><p>The remaining single-dose containers should be kept in the aluminium pouch.</p><p>If a drop misses your eye, try again.</p><p>If you use more IKERVIS than you should, rinse your eye with water. Do not put in any more drops until it is time for your next regular dose.</p><p>If you forget to use IKERVIS, continue with the next dose as planned. Do not use a double dose to make up for the forgotten dose. Do not use more than one drop each day in the affected eye(s).</p><p>If you stop using IKERVIS without speaking to your doctor, the inflammation of the transparent front part of your eye (known as keratitis) will not be controlled and could lead to impaired vision.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The following side effects have been reported:</p><p>The most common side effects are in and around the eyes.</p><p>Very common (may affect more than 1 in 10 people)</p><ul><li>Eye pain,</li><li>Eye irritation</li></ul><p>Common (may affect up to 1 in 10 people)</p><ul><li>Redness of the eyelid,</li><li>Watery eyes,</li><li>Eye redness,</li><li>Blurred vision,</li><li>Swelling of the eyelid,</li><li>Redness of the conjunctiva (thin membrane covering the front part of the eye),</li><li>Itching in the eye</li></ul><p>Uncommon (may affect up to 1 in 100 people)</p><ul><li>Discomfort in or around the eye when the drops are put into the eye, including feeling that there is something in the eye,</li><li>Irritation or swelling of the conjunctiva (thin membrane covering the front part of the eye),</li><li>Tear disorder,</li><li>Eye discharge,</li><li>Irritation or inflammation of the conjunctiva (thin membrane covering the front part of the eye),</li><li>Inflammation of the iris (coloured part of the eye) or eyelid,</li><li>Deposits in the eye,</li><li>Abrasion to the outer layer of the cornea,</li><li>Red or swollen eyelids,</li><li>Cyst in the eyelid,</li><li>Immune response or scarring in the cornea,</li><li>Itching in the eyelid,</li><li>Bacterial infection or inflammation of the cornea (transparent front part of the eye),</li><li>Painful rash around the eye caused by the herpes zoster virus,</li><li>Headache</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store ikervis",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store ikervis"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the outer carton, the aluminium pouch and on the single-dose containers after EXP . The expiry date refers to the last day of that month.</p><p>Do not freeze. Store below 25 C. After opening of the aluminium pouches, the single-dose containers should be kept in the pouches in order to protect from light and avoid evaporation. Discard any opened individual single-dose container with any remaining emulsion immediately after use.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What IKERVIS contains</p><ul><li>The active substance is ciclosporin. One millilitre of IKERVIS contains 1 mg of ciclosporin.</li><li>The other ingredients are medium-chain triglycerides, cetalkonium chloride, glycerol, tyloxapol, poloxamer 188, sodium hydroxide (for pH adjustment) and water for injections.</li></ul><p>What IKERVIS looks like and contents of the pack IKERVIS is a milky white eye drops emulsion.</p><p>It is supplied in single-dose containers made of a low-density polyethylene (LDPE). Each single-dose container contains 0.3 mL eye drops, emulsion. The single-dose containers are wrapped in a sealed aluminium pouch.</p><p>Pack sizes: 30 and 90 single-dose containers. Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder SANTEN Oy Niittyhaankatu 33720 Tampere Finland</p><p>Manufacturer EXCELVISION Rue de la Lombardi re ZI la Lombardi re F-07100 Annonay France</p><p>SANTEN Oy Kelloportinkatu 1 33100 Tampere Finland</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Santen Oy T l/Tel : +32 (0) 24019Lietuva Santen Oy Tel: +370 37 366<br/>Santen Oy Te .: +359 (0) 888 755 Luxembourg/Luxemburg Santen Oy T l/Tel: +352 (0) 27862 esk republika Santen Oy Tel: +358 (0) 3 284 8Magyarorsz g Santen Oy Tel.: +358 (0) 3 284 8Danmark Santen Oy Tlf: +45 898 713 Malta Santen Oy<br/>Tel: + 358 (0) 3 284 8Deutschland Santen GmbH Tel: +49 (0) 3030809Nederland Santen Oy<br/>Tel: +31 (0) 207139Eesti Santen Oy<br/>Tel: +372 5067Norge Santen Oy Tlf: +47 21939<br/>Santen Oy<br/>: + 358 (0) 3 284 8 sterreich Santen Oy Tel: +43 (0) 720116Espa a Santen Pharmaceutical Spain S.L. Tel: + 34 914 142 Polska Santen Oy Tel.: +48(0) 221042France Santen S.A.S. T l: +33 (0) 1 70 75 26 Portugal Santen Oy Tel: + 351 308 805 Hrvatska Santen Oy Tel: + 358 (0) 3 284 8Rom nia Santen Oy Tel: +358 (0) 3 284 8Ireland Santen Oy Tel: + 353 (0) 16950Slovenija Santen Oy Tel: + 358 (0) 3 284 8 sland Santen Oy S mi: + 358 (0) 3 284 8Slovensk republika Santen Oy Tel: +358 (0) 3 284 8Italia Santen Italy S.r.l. Tel: +39 0236009Suomi/Finland Santen Oy Puh/Tel: +358 (0) 974790<br/>Santen Oy<br/>: + 358 (0) 3 284 8Sverige Santen Oy Tel: +46 (0) 850598Latvija Santen Oy<br/>Tel: +371 677 917 United Kingdom (Northern Ireland) Santen Oy Tel: +353 (0) 16950(UK Tel: +44 (0) 345 075 4863)</p><p>This leaflet was last revised in</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp1f85f95883d4c92167ca0868ad5c50fd",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp1f85f95883d4c92167ca0868ad5c50fd",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp1f85f95883d4c92167ca0868ad5c50fd\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp1f85f95883d4c92167ca0868ad5c50fd</b></p><a name=\"mp1f85f95883d4c92167ca0868ad5c50fd\"> </a><a name=\"hcmp1f85f95883d4c92167ca0868ad5c50fd\"> </a><a name=\"mp1f85f95883d4c92167ca0868ad5c50fd-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/15/990/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: IKERVIS 1 mg/mL eye drops, emulsion</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/15/990/001"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "IKERVIS 1 mg/mL eye drops, emulsion",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
